Skip to main content

Disease reactivation after switching from natalizumab to daclizumab

Journal of Neurology volume 264, pages 2491–2494 (2017)Cite this article

Abstract

Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Schwab N, Schneider-Hohendorf T, Pignolet B et al (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3:e195

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F (2014) Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 261:1170–1177

    Article  CAS  PubMed  Google Scholar 

  3. Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G (2015) Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 8:233–238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Berger B, Baumgartner A, Rauer S et al (2015) Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol 282:118–122

    Article  CAS  PubMed  Google Scholar 

  5. Alping P, Frisell T, Novakova L et al (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79:950–958

    Article  CAS  PubMed  Google Scholar 

  6. Rasenack M, Derfuss T (2016) Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother 16:587–594

    Article  CAS  PubMed  Google Scholar 

  7. Cohen M, Maillart E, Tourbah A et al (2014) Club Francophone de la Sclerose en Plaques, Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 71:436–441

    Article  PubMed  Google Scholar 

  8. Fox RJ, Cree BA, De Seze J et al (2014) Restore, MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82:1491–1498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Iaffaldano P, Lucisano G, Pozzilli C et al (2015) Italian iMed-Web, Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain: J Neurol 138:3275–3286

    Article  Google Scholar 

  10. Kappos L, Radue EW, Comi G, T.s. group et al (2015) Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 85:29–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jokubaitis VG, Li V, Kalincik T, M.S.S. Group et al (2014) Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82:1204–1211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bielekova B, Richert N, Howard T et al (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705–8708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Cheryl Ernest for proofreading and editing the manuscript.

Author information

Authors and Affiliations

  1. Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, Mainz, 55131, Germany

    Timo Uphaus, Sergiu Groppa, Frauke Zipp & Stefan Bittner

  2. Department of Neurology, St. Vincenz-Hospital Limburg, 65549, Limburg an der Lahn, Germany

    Christoph Oberwittler

Authors
  1. Timo Uphaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Oberwittler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergiu Groppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frauke Zipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan Bittner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Bittner.

Ethics declarations

Conflicts of interest

FZ has received research grants from Teva, Merck Serono, Novartis and Bayer as well as consultation funds from Teva, Merck Serono, Novartis, Bayer Healthcare, Biogen Idec Germany, ONO, Genzyme, Sanofi-Aventis and Octapharma. Her travel compensation has been provided for by the aforementioned companies. S. B. has received consultation funds and travel compensation from Biogen Idec, Sanofi-Genzyme, Roche and Merck Serono. C.O. has received travel compensation from Genzyme. T.U. and S.G. declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the German Research Council (DFG, CRC-TR-128).

Ethical standards

All procedures performed in studies involving humans participants were in accordance with the ethical standard of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendment or comparable ethical standards.

Informed consent

The patient was informed on the intention to publish the case report and gave their consent.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uphaus, T., Oberwittler, C., Groppa, S. et al. Disease reactivation after switching from natalizumab to daclizumab. J Neurol 264, 2491–2494 (2017). https://doi.org/10.1007/s00415-017-8622-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-017-8622-9

Keywords

  • Multiple Sclerosis
  • Daclizumab
  • Natalizumab
  • Rebound
  • Disease reactivation
  • Relapse